Tata Medical Center | Tata Translational Cancer Research Center

Research site

(Unclaimed)

Location

14 MAR (E-W), New Town, Rajarhat, Kolkata, West Bengal, India

Site insights

Top conditions

Top treatments

Daratumumab

Lenalidomide

Amivantamab

Lazertinib

Ibrutinib

Teclistamab

Degarelix

Gemcitabine

ImbruvicaTM

Inavolisib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 26 total trials

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.

Enrolling

Relapsed or Refractory Multiple Myeloma

Drug: Dexamethasone

Drug: Pomalidomide

A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, p...

Enrolling

Relapsed Advanced Lymphomas

Drug: AUR108

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA)

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with ep...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Lazertinib

Drug: Amivantamab

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) a...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Pemetrexed

Drug: Carboplatin

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON)

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Pemetrexed

Drug: Amivantamab

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (VEGA)

The purpose of this study is to provide continued access to treatment for participants who continue to benefit from treatment.

Active, not recruiting

Lymphoma, Mantle-Cell

Drug: Rituximab

Drug: Ibrutinib

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Drug: Carboplatin

Drug: LY3537982

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)

The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in comb...

Enrolling

Multiple Myeloma

Drug: Lenalidomide

Drug: Talquetamab

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcuta...

Enrolling

Metastatic Breast Cancer

Drug: Inavolisib

Drug: Optional Endocrine Therapy of Investigator's Choice

A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (POLARGO)

This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with rituximab, gemcita...

Active, not recruiting

Diffuse Large B-Cell Lymphoma

Drug: Gemcitabine

Drug: Polatuzumab Vedotin

Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer (ARANOTE)

The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in pati...

Active, not recruiting

Prostatic Neoplasms

Other: Androgen deprivation therapy (ADT)

Drug: Placebo

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbocic...

Enrolling

Breast Cancer

Drug: Alpelisib

Drug: Fulvestrant

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control)...

Enrolling

Multiple Myeloma

Drug: Lenalidomide

Drug: Elranatamab